An intravenous infusion of bortezomib is an approved and effective way of treating relapsed multiple myeloma, however there are concerns about the levels of toxicity for this treatment. Prof Philippe Moreau talks about a phase III trial which compared subcutaneous delivery of bortezomib with intravenous delivery. Both methods achieved equal response rates however subcutaneous administration was associated with a reduced level of toxicity. This lower toxicity level will allow clinicians to use bortezomib over a longer period of time. Prof Moreau discusses these results and explains how he believes they will impact clinical practice.